Home » Regions » Global News » KineMed, Pfizer partner on biomarkers

KineMed, Pfizer partner on biomarkers

Monday, January 4, 2016

KineMed, a U.S. based biotech company, has entered into a strategic collaboration with Pfizer to discover and develop novel proprietary biomarkers in various fields of unmet medical need.

KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilizing mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.

Pfizer has licensed access to the KineMed platform and rights to pursue discovery, development and potential commercialization of kinetic biomarkers in various fields. Both companies will work together on discovery research of novel biomarkers, and Pfizer will be responsible for the development and potential commercialization of any novel biomarkers or companion diagnostics for the Pfizer-selected targets.

KineMed will receive an upfront payment, as well as funding for R&D costs associated with Pfizer-selected targets. In addition, KineMed is eligible to receive development and regulatory milestone payments.

“We believe our kinetic biomarker platform provides real advantages over other approaches to biomarker discovery in de-risking and advancing medicines development, and this collaboration with Pfizer is an important step toward helping us realize the full potential of this technology,” said KineMed President Patrick Doyle.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!